| Autor: |
Mahoko Ikeda, Yoshitaka Wakabayashi, Koh Okamoto, Shintaro Yanagimoto, Shu Okugawa, Kyoji Moriya |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
AIDS Research and Therapy, Vol 18, Iss 1, Pp 1-7 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1742-6405 |
| DOI: |
10.1186/s12981-021-00354-y |
| Popis: |
Abstract Background Antiretrovirals, including tenofovir, can suppress human immunodeficiency virus (HIV) infection but cannot completely eradicate it. Patients with HIV infection are administered antiretroviral drugs over a long term; thus, managing consequent adverse drug reactions, such as renal dysfunction and bone mineral loss, is important. Currently, highly sensitive biomarkers that can detect adverse drug reactions early have not been well studied. Methods This single-center, prospective, observational study explored changes in the biomarkers of renal function, bone metabolism, and lipid profile before and after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in patients with HIV infection. Results All 31 enrolled patients had been treated with antiretrovirals for more than 5 years. The rate of proteinuria decreased significantly after starting TAF-containing antiretroviral regimen. The urinary liver-type fatty acid binding protein (L-FABP)/creatinine ratio was significantly decreased at 3 and 6 months after switching to TAF compared with that before switching to TAF (− 0.5 μg/g Cr at 3 months, and − 0.8 μg/g Cr at 6 months; p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
